Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Recommendation of Buy by Analysts

Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has been assigned an average rating of “Buy” from the nine brokerages that are covering the stock, MarketBeat reports. Nine research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in […]

Related Keywords

Canada ,United States ,China , ,Needham Company ,China Universal Asset Management Co ,Rathbones Group ,Corton Capital Inc ,Pliant Therapeutics Inc ,Nasdaq ,Royal Bank ,Oppenheimer Co ,Quest Partners ,Pliant Therapeutics ,Get Free Report ,Universal Asset Management ,Get Free ,Pliant Therapeutics Daily ,Nasdaq Plrx ,Plrx ,Medical ,Ratings ,Consensus ,